Ovarian Carcinoma
154
37
56
50
Key Insights
Highlights
Success Rate
68% trial completion
Published Results
30 trials with published results (19%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.9%
23 terminated out of 154 trials
68.5%
-18.0% vs benchmark
6%
9 trials in Phase 3/4
60%
30 of 50 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 50 completed trials
Clinical Trials (154)
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
The Vanguard Study: Testing a New Way to Screen for Cancer
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
A Study of Intra-operative Imaging in Women With Ovarian Cancer
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
National Cancer Institute "Cancer Moonshot Biobank"